These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 1973045)

  • 1. Low dose oral alpha-interferon therapy for patients seropositive for human immunodeficiency virus type-1 (HIV-1).
    Koech DK; Obel AO; Minowada J; Hutchinson VA; Cummins JM
    Mol Biother; 1990 Jun; 2(2):91-5. PubMed ID: 1973045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An interim report on the effect of natural human interferon alpha (IFN-alpha) lozenges in patients seropositive for the human immunodeficiency virus type 1 (HIV-1).
    Babiuch L; Mian M; Kamińska E; Szymańska B; Georgiades JA
    Arch Immunol Ther Exp (Warsz); 1993; 41(3-4):213-9. PubMed ID: 7907465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of intervention with or without low dose oral interferon alpha in thirty-two HIV-1 seropositive patients in a referral hospital.
    Obel AO; Koech DK
    East Afr Med J; 1990 Jul; 67(7 Suppl 2):SS71-6. PubMed ID: 1977577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Kemron (low dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS).
    Koech DK; Obel AO
    East Afr Med J; 1990 Jul; 67(7 Suppl 2):SS64-70. PubMed ID: 2226235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral use of human alpha interferon in cats.
    Cummins JM; Tompkins MB; Olsen RG; Tompkins WA; Lewis MG
    J Biol Response Mod; 1988 Oct; 7(5):513-23. PubMed ID: 3183686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial.
    Hurwitz BE; Klaus JR; Llabre MM; Gonzalez A; Lawrence PJ; Maher KJ; Greeson JM; Baum MK; Shor-Posner G; Skyler JS; Schneiderman N
    Arch Intern Med; 2007 Jan; 167(2):148-54. PubMed ID: 17242315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular manifestations in HIV-seropositive patients.
    Balacco Gabrieli C; Angarano G; Moramarco A; LoCaputo S; Castellano L
    Ann Ophthalmol; 1990 May; 22(5):173-6. PubMed ID: 1973340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fleroxacin in the treatment of chancroid: an open study in men seropositive or seronegative for the human immunodeficiency virus type 1.
    Tyndall MW; Plourde PJ; Agoki E; Malisa W; Ndinya-Achola JO; Plummer FA; Ronald AR
    Am J Med; 1993 Mar; 94(3A):85S-88S. PubMed ID: 8452188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.
    Lapenta C; Santini SM; Proietti E; Rizza P; Logozzi M; Spada M; Parlato S; Fais S; Pitha PM; Belardelli F
    Virology; 1999 Oct; 263(1):78-88. PubMed ID: 10544084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct comparison of the relationship between clinical outcome and change in CD4+ lymphocytes in human immunodeficiency virus-positive homosexual men and injecting drug users.
    Margolick JB; Muñoz A; Vlahov D; Astemborski J; Solomon L; He XY; Nelson KE; Saah AJ
    Arch Intern Med; 1994 Apr; 154(8):869-75. PubMed ID: 7908795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.
    Clerici M; Stocks NI; Zajac RA; Boswell RN; Lucey DR; Via CS; Shearer GM
    J Clin Invest; 1989 Dec; 84(6):1892-9. PubMed ID: 2574188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level.
    Wright PW; Hoesley CJ; Squires KE; Croom-Rivers A; Weiss HL; Gnann JW
    Clin Infect Dis; 2003 Jan; 36(2):207-11. PubMed ID: 12522754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of highly active anti-retroviral therapy on CD3+/CD4+/CD8+ T lymphocyte counts in HIV seropositive Kashmiri patients: a follow up study.
    Shah ZA; Rasool R; Siddiqi MA
    Indian J Pathol Microbiol; 2007 Jul; 50(3):648-51. PubMed ID: 17883172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the frequency of interleukin (IL)-2-, interferon-gamma-, and IL-4-producing T cells in 2 diseases, human immunodeficiency virus types 1 and 2, with distinct clinical outcomes.
    Sousa AE; Chaves AF; Loureiro A; Victorino RM
    J Infect Dis; 2001 Sep; 184(5):552-9. PubMed ID: 11494161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection.
    King MD; Reznik DA; O'Daniels CM; Larsen NM; Osterholt D; Blumberg HM
    Clin Infect Dis; 2002 Mar; 34(5):641-8. PubMed ID: 11803508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic abnormalities related to antigenaemia during HIV-1 infection.
    De Paoli P; Battistin S; Crovatto M; Modolo ML; Carbone A; Tirelli U; Santini G
    Clin Exp Immunol; 1988 Dec; 74(3):317-20. PubMed ID: 2976619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated peripheral CD8 lymphocytes express CD4 in vivo and are targets for infection by human immunodeficiency virus type 1.
    Imlach S; McBreen S; Shirafuji T; Leen C; Bell JE; Simmonds P
    J Virol; 2001 Dec; 75(23):11555-64. PubMed ID: 11689637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-latency event-related potentials in asymptomatic human immunodeficiency virus type 1 infection.
    Connolly S; Manji H; McAllister RH; Fell M; Loveday C; Kirkis C; Herns M; Sweeney B; Sartawi O; Durrance P
    Ann Neurol; 1994 Feb; 35(2):189-96. PubMed ID: 7906501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of circulating HIV antigens in seropositive patients after treatment with AL-721.
    Yust I; Vardinon N; Skornick Y; Zakuth V; Hasner A; Shinitzky M
    Isr J Med Sci; 1990 Jan; 26(1):20-6. PubMed ID: 2179157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose oral recombinant interferon-alpha A in patients with HIV-1 infection: a blinded pilot study.
    Sperber SJ; Gocke DJ; Haberzettl CA; Pestka S
    AIDS; 1993 May; 7(5):693-7. PubMed ID: 8100421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.